Anti-Dopamine Transporter/SLC6A3 Polyclonal Antibody for WB, IF-P, IHC-P, ELISA - Q01959

Core Product Specifications and Parameters

Biological Background: Dopamine Transporter/SLC6A3 Function and Localization

• The sodium-dependent dopamine transporter (DAT), encoded by the SLC6A3 (DAT1) gene, is responsible for terminating dopaminergic neurotransmission by mediating sodium- and chloride-dependent reuptake of dopamine from the synaptic cleft (PubMed:10375632, PubMed:11093780, PubMed:1406597). Related references: PMID:10375632 PMID:11093780 PMID:1406597
• In addition to dopamine, DAT also transports norepinephrine with similar ionic dependencies, contributing to the regulation of catecholamine signaling (By similarity).
• DAT is predominantly localized to the cell membrane of neurons, specifically enriched in neuron projections, axons, and axonal varicosities of dopaminergic nerve terminals.
• Expression is highest in the substantia nigra (PubMed:7637582) and striatum (PubMed:17296554), key brain regions for motor control and reward processing; protein expression has been confirmed in axonal varicosities (PubMed:17296554). Related references: PMID:7637582 PMID:17296554
• The protein is a member of the solute carrier 6 (SLC6) neurotransmitter transporter family and contains twelve transmembrane helices, forming the substrate and ion binding sites.
• Post-translational modifications include N-linked glycosylation and disulfide bonds, which are critical for transporter folding and plasma membrane targeting.
• Genetic variations in SLC6A3 are associated with neurological disorders, including Parkinsonism and dystonia, as highlighted by disease-related keywords.
• Beyond dopamine transport, DAT has been implicated in light-dependent retinal hyaloid vessel regression in animal models, indicating potential non-neuronal functions (By similarity).

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal intracellular domain (aa 1-100); for immunofluorescence (IF) and immunohistochemistry (IHC), permeabilization is recommended to ensure antibody access.
• For Western blot (WB), a band at approximately 68 kDa is expected; include appropriate positive and negative controls to confirm specificity.
• In IHC–paraffin (IHC-P) and IF–paraffin (IF-P) applications, antigen retrieval using heat-mediated citrate buffer may improve detection; test with brain tissue sections known to express DAT.
• For ELISA, the polyclonal antibody can be used as either capture or detection reagent; optimize coating concentrations and blocking conditions for best signal-to-noise ratio.
• Cross-reactivity with mouse and rat has been noted; however, sequence alignment between species in the immunogen region should be considered when interpreting results.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides comprehensive supply solutions for IVD raw materials, including validated antibody pairs, recombinant antibodies, and ancillary reagents tailored to neuroscience and transporter research. With expertise in rare target sourcing and bulk production, we support diagnostic manufacturers and research labs from assay development to scale-up. For your Dopamine Transporter studies, inquire about our optimized polyclonal and monoclonal antibody options and complementary reagents to streamline your workflow.